| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 05/18/2004 | US6737075 Using enzyme for the manufacture of a medicament to eliminate corneal scar, opacity, and haze |
| 05/18/2004 | CA2090911C Aqueous pharmaceutical formulations of sodium cromoglycate |
| 05/13/2004 | WO2004039972A1 H17t213-transgenic animal, novel h17t213 protein and dna thereof |
| 05/13/2004 | WO2004039403A1 Remedy for corneal failure |
| 05/13/2004 | WO2004039366A1 Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| 05/13/2004 | WO2004022529A3 Diarylurea derivatives and their use as chloride channel blockers |
| 05/13/2004 | WO2003080022A3 Analgesics for nasal administration |
| 05/13/2004 | WO2003059194A3 Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs |
| 05/13/2004 | US20040092744 Process for preparing crystalline form I of cabergoline |
| 05/13/2004 | US20040092594 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof |
| 05/13/2004 | US20040092576 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses |
| 05/13/2004 | US20040092569 Analgesics, antiinflammatory agents, autoimmune diseases, bone disorders, central nervous system disorders |
| 05/13/2004 | US20040092545 Sulfonamido ether substituted imidazoquinolines |
| 05/13/2004 | US20040092533 Central nervous system disorders; anxiolytic agents; anticonvulsants; cognition activators; side effect reduction |
| 05/13/2004 | US20040092518 Compounds for the treatment of metabolic disorders |
| 05/13/2004 | US20040092516 Insulin resistance; antidiabetic agents; antilipemic agents; anticholesterol agents; cardiovascular disorders |
| 05/13/2004 | US20040092506 Administering estrogen antagonist; skin disorders; wrinkle resistance; antiarthritic agents; anticancer agents; wound healing agents |
| 05/13/2004 | US20040092497 Heteroarylakanoic acids as intergrin receptor antagonists |
| 05/13/2004 | US20040092486 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders |
| 05/13/2004 | US20040092454 3-biphenyl-4-yl-3-(2-(4-(pyridin-2-ylamino)pentanoylamino)-pen tanoyl amino)propionic acid derivatives |
| 05/13/2004 | US20040092447 Uses of kappa-conotoxin PVIIA |
| 05/13/2004 | US20040092444 Neuroprotective synergy of erythropoietin and insulin-like growth factor |
| 05/13/2004 | US20040092435 Treatment of ocular disease |
| 05/13/2004 | US20040091912 Diagnostic method |
| 05/12/2004 | EP1418167A2 Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders |
| 05/12/2004 | EP1417976A1 Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect |
| 05/12/2004 | EP1417304A2 Method and composition for inhibiting heparanase activity |
| 05/12/2004 | EP1417228A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 05/12/2004 | EP1417227A2 Peptides eefective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 05/12/2004 | EP1417205A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| 05/12/2004 | EP1417191A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |
| 05/12/2004 | EP1417181A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |
| 05/12/2004 | EP1416941A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 05/12/2004 | EP1416940A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine |
| 05/12/2004 | EP1416931A1 Inhibitors of polyq-aggregation |
| 05/12/2004 | EP1416795A1 Compositions and methods for treatment of mitochondrial diseases |
| 05/12/2004 | EP1265903B1 Thiepino[3,2-b]dihydropyridines and related compositions and methods |
| 05/12/2004 | EP1161410B1 Retinoid antagonists and use thereof |
| 05/12/2004 | EP1112070B1 Novel substituted triazole compounds |
| 05/12/2004 | EP1067966B1 Ophthalmic composition comprising a beta-blocker |
| 05/12/2004 | EP1054662B1 Water-soluble eye drop |
| 05/12/2004 | EP1036065B1 Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors |
| 05/12/2004 | CN1496270A Pharmaceutical composition based on macrolides for topical application in ophthalmology |
| 05/12/2004 | CN1496264A 4-fluoro-N-indan-2-Y1 benzamide and its use as pharmaceutical |
| 05/12/2004 | CN1495262A Non-splicing variant of gp 350/220 |
| 05/12/2004 | CN1495171A Indazol compound for inhibiting protein kinase and medicine composition and their application |
| 05/12/2004 | CN1495169A Pyridine-3-carboxylic acid derivative |
| 05/12/2004 | CN1494903A Preventing or curing agent for eye fatigue and pseudomyopia |
| 05/12/2004 | CN1494901A Yanming qingsong plaster and it preparation method |
| 05/12/2004 | CN1149191C Azetidine derivatives, Preparation and medicines containing them |
| 05/11/2004 | US6734306 N-benzenesulfonyl L-proline compounds as bradykinin antagonists |
| 05/11/2004 | US6734284 Exhibits high affinity for the gfr alpha 3- ret receptor complex and unique subregions in its amino acid sequence |
| 05/11/2004 | US6734206 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| 05/11/2004 | US6734201 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
| 05/11/2004 | US6734189 Hydroxamic and carboxylic acid derivatives |
| 05/11/2004 | US6734183 Useful as metalloproteinase inhibitor; piperazino-sulfonamide or piperidino-sulfonamide compound |
| 05/11/2004 | US6733990 Useful for the treatment of immune, hematologic, fibrotic, hepatic, and respiratory disorders such as asthma using g-protein coupled receptors (gpcr) |
| 05/11/2004 | US6733973 Diagnostic reagents for human cytomegalovirus and methods of use |
| 05/11/2004 | US6733754 Adjuvants for use in vaccines |
| 05/11/2004 | CA2279428C Compounds and methods for therapeutic intervention in preventing diabetic complications |
| 05/11/2004 | CA2104594C Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| 05/08/2004 | WO2004064828A1 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
| 05/06/2004 | WO2004037829A1 Novel benzoxazole or oxazolopyridine compounds, method for preparing same and pharmaceutical compositions containing same |
| 05/06/2004 | WO2004037817A1 N-oxide compounds |
| 05/06/2004 | WO2004037813A1 Pyrrolidin-2-on derivatives as ep4 receptor agonists |
| 05/06/2004 | WO2004037251A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 |
| 05/06/2004 | WO2004037246A1 Nerve fiber regeneration accelerator |
| 05/06/2004 | WO2004037173A2 Method for treating erectile dysfunction and increasing libido in men |
| 05/06/2004 | WO2004037167A2 Methods of treating dry eye disease with lantibiotics |
| 05/06/2004 | WO2004018451A8 Pyridazinone-derivatives as pde4 inhibitors |
| 05/06/2004 | WO2004013119B1 The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
| 05/06/2004 | WO2004010950A3 Aryl substituted hydantoin compounds and their use as sodium channel blockers |
| 05/06/2004 | WO2004000042A3 Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress |
| 05/06/2004 | WO2003106416A3 Chemical process |
| 05/06/2004 | WO2003092580A3 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
| 05/06/2004 | WO2003051365A9 Use of compounds of the benzamide family as immunosuppressant |
| 05/06/2004 | WO2003020219B1 Aerosolized decongestants for the treatment of sinusitis |
| 05/06/2004 | WO2003005971A8 Tetracycline compounds having target therapeutic activities |
| 05/06/2004 | WO2003004467A3 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 05/06/2004 | WO2002057222A9 Thiol-based naaladase inhibitors |
| 05/06/2004 | WO2002020512A9 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation |
| 05/06/2004 | US20040087801 Renin inhibitors; congesitive heart failure; glaucoma |
| 05/06/2004 | US20040087796 Substituted carbazoles as inhibitors of spla2 |
| 05/06/2004 | US20040087792 Tryptase-inhibitors |
| 05/06/2004 | US20040087657 Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
| 05/06/2004 | US20040087654 Nitric oxide synthase inhibitor phosphate salt |
| 05/06/2004 | US20040087646 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 05/06/2004 | US20040087640 Administering by mouth; cyclooxygenase inhibitor; controlling particle size |
| 05/06/2004 | US20040087630 Combinations |
| 05/06/2004 | US20040087624 Analgesics; antiinflammatory agents; immunology; bone disorders; neurodegradation diseases |
| 05/06/2004 | US20040087621 N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists |
| 05/06/2004 | US20040087604 Immunosuppressants; antiallergens |
| 05/06/2004 | US20040087598 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-1,3-dihydoimidazo{1,2-a}pyrimidin-5(1h)one derivatives |
| 05/06/2004 | US20040087597 Preventives and remedies for complications of diabetes |
| 05/06/2004 | US20040087590 Novel biphenyl and biphenyl-like cannabinoids |
| 05/06/2004 | US20040087574 Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient |
| 05/06/2004 | US20040087566 Enzyme inhibitors; anticancer agents |
| 05/06/2004 | US20040087510 Cardiovascular diseases and disorders; sustained delivery of nitric oxide |
| 05/06/2004 | US20040087486 Inhibiting vascular occlusive events; reducing circulating count below normal levels without serious adverse consequence |
| 05/06/2004 | US20040087035 Using myeloproliferative leukemic inhibitory agents to treatment and/ or prevention platelet related thrombotic and vaso-occlusive disorder |